Product Description
Azilsartan medoxomil (Edarbi, Takeda) is a new addition to the ARB class of antihypertensive agents. As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278144/)
Mechanisms of Action: ARB Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Canada | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Mexico | Netherlands | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Russia
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06990204 |
JSC Nizhpharm, Russia | P1 |
Not yet recruiting |
Hypertension |
2025-07-01 |
50% |
2025-05-28 |
Primary Endpoints|Treatments |
CTR20241615 |
CTR20241615 | P1 |
Completed |
Hypertension |
2024-07-23 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |